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Background: B7 costimulatory molecules are expressed on antigen presenting cells (APCs) and are important
regulators of T cell activation. We investigated the role of the B7 family of costimulatory molecules in the
development of the systemic maternal immune tolerance during healthy pregnancy (HP). We also aimed to
investigate the intracellular expression of indoleamine-2,3-dioxygenase (IDO) and plasma levels of tryptophane
(TRP), kynurenine (KYN) and kynurenic acid (KYNA), important molecules with immunoregulatory properties, in order
to describe their potential contribution to the pregnancy-specific maternal immune tolerance.
Methods: We determined the frequency of activated (CD11b+) monocytes expressing B7-1, B7-2, B7-H1, and B7-H2,
and that of T cells and CD4+ T helper cells expressing CD28, CTLA-4, PD-1, and ICOS in peripheral blood samples of
healthy pregnant (HP) and non-pregnant (NP) women using flow cytometry. We also examined the intracellular
expression of IDO applying flow cytometry and plasma levels of TRP, KYN and KYNA using high-performance liquid
chromatography.
Results: A significant increase in the prevalence of CD28+ T cells was observed in HP compared to NP women. At the
same time a decrease was shown in the expression of CTLA-4 on these cells. The frequency of CD80+ monocytes was
lower in HP women. The prevalence of IDO-expressing T cells and monocytes was higher in HP compared to NP
women. Plasma KYN, KYNA and TRP levels were lower, while at the same time, the KYN/TRP ratio was higher in HP than
in NP women.
Conclusions: Costimulation via CD28 may not contribute to the immunosuppressive environment, at least in the
third trimester of pregnancy. The development of the pregnancy-specific immune tolerance in the mechanism of
B7 costimulation may be more related to the altered expression of B7 proteins on APCs rather than that of their
receptors on T cells. The elevated intracellular IDO expression in monocytes and T cells, as well as higher plasma
enzymatic IDO activity are likely to contribute to the systemic immunosuppressive environment in the third
trimester characteristic for healthy gestation.
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Since the conceptus is half of foreign origins, presenting pa-
ternal antigens, it is considered a semi-allograft to maternal
immunity. Therefore, a maternal immune tolerance must
develop to avoid immunological rejection of the fetus. The
alterations contributing to maternal tolerance are present
not only at the maternal-fetal interface, but also at the sys-
temic level. Several components of this pregnancy-specific
immune tolerance have been described over the recent
years [1]. One of the most important factors is the
decreased level of activation of T cells compared to the
non-pregnant state. The second and third trimesters of
pregnancy are characterized by a shift of the inflammatory
balance towards the anti-inflammatory direction via the
upregulation of Th2 cells [2] and a decrease in the Th17/
regulatory T cell (Treg) ratio [3]. The kinetics of calcium in-
flux upon stimulation via the T cell receptor (TCR) is
decreased in Th1 and CD8 cells compared to lymphocytes
isolated from non-pregnant women [4]. Several other
factors may account for the decreased level of peripheral
T lymphocyte activation in healthy pregnancy (HP).
B7 costimulatory molecules are expressed on antigen pre-
senting cells (APCs) and are important regulators of T cell
activation (Figure 1). Besides the ligation of the T cell recep-
tor (TCR) by the antigen associated with major histocom-
patibility complex (MHC) molecules, a costimulatory signal
occurs through CD28, inducing the production of IL-2 in T
cells, thus protecting them from apoptosis and anergy [5].
Without costimulation, the signal from the TCR induces
the tolerance of T cells to their cognate antigen instead of
being activated [6].
On the other hand, B7 proteins mediate not only stimula-
tory, but also inhibitory effects on T cells, thus potentially
contributing to the lower reactivity of T lymphocytes in HP
[5]. Upon the stimulation of the TCR, cytotoxic T lympho-
cyte antigen 4 (CTLA-4, CD154) becomes stabilized on theFigure 1 B7 family proteins on antigen-presenting cells (APCs) and thsurface of T cells, thus competing with CD28 for B7 bind-
ing and blocking the costimulatory signal. The affinity of
the inhibitory receptor, CTLA-4 is higher than that of
CD28 for B7-1 (CD80) and B7-2 (CD86). Besides its com-
petitive role, CTLA-4 also prevents T cell activation via the
emission of direct inhibitory signals [7].
Another B7 family member, B7-H1 (CD274) possesses
mostly inhibitory properties on T cells. This inhibitory func-
tion is mediated via programmed death-1 receptor (PD-1,
CD279), which induces apoptosis or anergy of self-reactive
T cells. B7-H2 (CD275) serves as the ligand for inducible
costimulator of T cells (ICOS, CD278), and promotes T cell
activation, differentiation, and effector responses [8]. In con-
trast to the costimulatory effect of CD28, ICOS most effect-
ively induces IL-10 instead of IL-2 production [9].
Besides initiating signal transduction in T lymphocytes,
B7-1 and B7-2 may back-signal into the APC and influ-
ence the local immune environment through induced ex-
pression of immunosuppressive factors independently of
their effects on T cells [5]. Reverse signalling through B7-1
and B7-2 was shown to upregulate the tryptophan (TRP)
catabolic enzyme, indoleamine 2,3-dioxygenase (IDO)
[10]. The potent immunosuppressive activity of IDO was
first identified in pregnancy, when it was demonstrated
that inhibition of IDO abolished allogenic gestation in
mice [11]. In the first steps of the kynurenine (KYN) path-
way, TRP is transformed into KYN by IDO. KYN is then
further metabolized by different enzymes. One of them is
kynurenine aminotransferase, leading to the production
of kynurenic acid (KYNA), a broad-spectrum endogenous
antagonist of excitatory amino acid receptors [12,13]
with emerging recent implications in immunomodulation
[14,15]. The rate of TRP degradation, represented by the
K/T (KYN to TRP) ratio, allows a good estimate of IDO
activity. The local depletion of TRP and the production of
pro-apoptotic TRP metabolites of the kynurenine pathway,eir cognate receptors on T cells.
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among the mechanisms potentially responsible for the im-
munosuppressive effects related to IDO [14].
In this study, we aimed to determine the frequency of
activated monocytes expressing B7-1, B7-2, B7-H1 and B-
7H2 costimulatory molecules, as well as that of T cells and
T helper cells expressing CD28, CTLA-4, PD-1 and ICOS
in peripheral blood samples of HP compared to non-
pregnant (NP) women. We also investigated the intracel-
lular expression of IDO in activated monocytes and T
cells, as well as plasma levels of TRP, KYN and KYNA.
Methods
Sample collection
Peripheral blood samples were taken from 20 healthy
pregnant (HP) women in the third trimester and 14 age-
matched, healthy non-pregnant (NP) women between
01/2012 and 08/2012. The latter group was synchro-
nized in terms of menstrual cycle for the luteal phase.
Clinical characteristics of participants are summarized
in Table 1. Informed consent was obtained from all sub-
jects, and our study was reviewed and approved by an
independent ethical committee of the institution (Scien-
tific and Research Ethics Committee, Semmelweis Uni-
versity, Budapest, Hungary). The study was adhered to
the tenets of the most recent revision of the Declaration
of Helsinki and to the STROBE guidelines for observa-
tional studies (checklist included as Additional file 1).
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated by a standard density gradient centrifugation (Ficoll
Paque, Amersham Biosciences AB, Uppsala, Sweden, 25 mi-
nutes, 400 g, 22°C) from freshly drawn blood collected in
lithium heparin-treated tubes (BD Vacutainer, BD Biosci-
ences, San Jose, CA, USA). Cells were kept at −80°C in
Fetal Bovine Serum containing 10% DMSO until analysis.
After thawing, cells were washed twice in phosphate-
buffered saline and their viability was assessed by trypan
blue exclusion (consistently > 90%).Table 1 Clinical characteristics of non-pregnant and
healthy pregnant women
Non-pregnant
women (n = 14)
Healthy pregnant
women (n = 20)
Age (years) 32 (27–34) 33.5 (30–36)
No. of primiparas - 12 (60%)
Gestational age at
blood collection (weeks)
- 36 (34–37)
Gestational age at
delivery (weeks)
- 39 (38–40)
Fetal birth weight (grams) - 3180 (2915–3725)
Data are presented as median (interquartile range) for continuous variables
and as number (percentage) for categorical variables.Flow cytometry
PBMCs were stained for 30 min at room temperature in the
dark with PerCP-conjugated CD3, PE Cy7-conjugated CD4,
PE-conjugated CD28, APC-conjugated CD152 (CTLA-4),
FITC-conjugated CD278 (ICOS) and APC-Cy7-conjugated
CD279 (PD-1) mAbs, or PerCP-conjugated CD3, PE Cy7-
conjugated CD11b, APC-conjugated CD80 (B7-1) and PE-
conjugated CD275 (B7-H2) mAbs, or PerCP-conjugated
CD3, PE Cy7-conjugated CD11b, APC-conjugated CD86
(B7-2) and PE-conjugated CD274 (B7-H1) mAbs in separate
tubes, respectively (BioLegend, San Diego, CA, USA). After
washing, cells were fixed with Fixation/Permeabilization so-
lution and treated with Permeabilization Buffer according to
the manufacturer’s instructions (eBioscience, San Diego,
CA, USA). They were then stained with a mouse anti-
human IDO monoclonal antibody (Millipore, USA) for
30 min at 4°C in the dark. After washing, cells were stained
with FITC-labelled goat anti-mouse antibody (Millipore,
USA) for 15 min at 4°C in the dark. After washing, cells
were analyzed on a BD FACSAria flow cytometer (BD Bio-
sciences) equipped with 488 nm and 633 nm excitation la-
sers. Data were processed using the FACSDiVa software.
100000 cells were recorded. The populations of lymphocytes
and monocytes were gated from PBMCs according to For-
ward Scatter Characteristics and Side Scatter Characteristics.
As control of FITC-labelled goat anti-mouse specificity
staining, PBMCs were incubated with surface antibodies
and FITC-labelled goat anti-mouse antibody in the absence
of mouse anti-human IDO monoclonal antibody. Figure 2
represents the measurement of intracellular IDO expression
by flow cytometry.
High-performance liquid chromatography (HPLC)
The investigated reference compounds (L-TRP, L-KYN
sulfate salt, KYNA) and zinc acetate dihydrate were pur-
chased from Sigma-Aldrich (Saint Louis, MO, USA),
acetonitrile and perchloric acid (PCA) were purchased
from Scharlau (Barcelona, Spain) and acetic acid was
purchased from VWR International (Radnar, PA, USA).
Plasma samples were stored at −80°C until analysis.
Before analysis, the samples were thawed and after a
brief vortex 300 μl of plasma sample was ‘shot’ onto
700 μl precipitation solvent (containing 3.57 w/w% PCA
and 2.857 μM 3-nitro-L-tyrosine as internal standard).
Following that the samples were centrifuged at 13000 g
for 10 min at 4°C, and the supernatant was collected.
The KYN, KYNA and TRP concentrations of the sam-
ples were quantified based on the slightly modified
method of Herve et al. [16], with an Agilent 1100 HPLC
system (Agilent Technologies, Santa Clara, CA, USA).
The system was equipped with a fluorescent and a UV
detector, the former was applied for the determination
of KYNA and TRP, and the latter for the determination
of KYN and the internal standard. Chromatographic
Figure 2 Indoleamine-2,3-dioxygenase (IDO) enzyme expression in CD3+ lymphocytes and CD11b +monocytes measured by flow
cytometry. FSC – forward scatter characteristics, SSC – side scatter characteristics.
Grozdics et al. BMC Pregnancy and Childbirth 2014, 14:306 Page 4 of 9
http://www.biomedcentral.com/1471-2393/14/306separations were performed on an Onyx Monolithic C18
column, 100 mm × 4.6 mm I.D. (Phenomenex Inc.,
Torrance, CA, USA) after passage through a Hypersil
ODS pre-column, 20 mm × 2.1 mm I.D., 5 μm particlesize (Agilent Technologies, Santa Clara, CA, USA) with a
mobile phase composition of 0.2 M zinc acetate/ACN =
95/5 (v/v%) with a pH adjusted to 6.2 with glacial acetic
acid, applying isocratic elution. The flow rate and the
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The fluorescent detector was set at excitation and emis-
sion wavelengths of 344 nm and 398 nm, and after
3.5 min of each run the wavelengths were changed to
254 nm and 398 nm. The UV detector was set at a wave-
length of 365 nm. Figure 3 shows representative chro-
matograms of the measured metabolites.
HPLC method validation
Calibration curve and linearity
Calibrants were prepared at 6 different concentration levels,
from 1 to 100 nM, 0.1 to 5 μM, 5 to 50 μM and 0.5 to
7.5 μM for KYNA, KYN, TRP and the internal standard, re-
spectively. Three parallel injections of each solution were
made under the chromatographic conditions described
above. The peak area responses were plotted against the
corresponding concentration, and the linear regression
computations were carried out by the least square method
with the R software [17]. Very good linearity was observed
throughout the investigated concentration ranges for KYN,
KYNA, TRP and the internal standard when either fluores-
cence or UV detection was applied.
Selectivity
The selectivity of the method was checked by comparing
the chromatograms of KYN, KYNA, TRP and the in-
ternal standard for a blank plasma sample and those for
a spiked plasma sample. All compounds could be de-
tected in their own selected chromatograms without any
significant interference.
LOD and LLOQ
Limit of detection (LOD) and lower limit of quantitation
(LLOQ) was determined via signal-to-noise ratio with
threshold 3 and 10, according to the ICH guidelines [18].
The LOD was 100, 1 and 15 nM, while LLOQ was 275,
3.75 and 35 nM for KYN, KYNA and TRP, respectively.
Precision
Replicate HPLC analysis showed that the relative stand-
ard deviation was ≤ 2.2% for the peak area response
and ≤ 0.1% for the retention time.
Recovery
The relative recoveries were estimated by measuring spiked
samples of KYN, KYNA and TRP at 2 different concentra-
tions with 3 replicates of each. No significant differences
were observed for the lower and higher concentrations.
The recoveries ranged from 108 to 110%, 86 to 91% and 85
to 89% for KYN, KYNA and TRP, respectively.
Statistics
Data are expressed as median and interquartile range.
The sample size was estimated to achieve 80% powerwith 0.45 effect size to detect differences between sam-
ple populations. Comparisons between sample popula-
tions were made with Mann–Whitney tests. Correlation
analyses were performed using Spearman tests. p-values
less than 0.05 were considered significant. Statistics were
calculated using the STATISTICA software (version 8.0;
StatSoft, Inc., Tulsa, Oklahoma, USA).
Results
Our results are detailed in Tables 2 and 3 and Figure 4. A
significant increase in the prevalence of CD28+ T cells
was observed in HP compared to NP women. At the same
time a decrease was shown in the expression of CD152 on
these cells. The prevalence of both CD278+ and CD279+
T cells was higher in HP than in NP women.
Within the CD4 subset, the ratio of CD28+, CD28+
CD152+ and CD279+ cells was comparable in HP and
NP women, while that of CD278+ cells was higher in
HP than in NP individuals.
The frequency of both CD80+ and CD275+ monocytes
was lower in HP women, however, no difference was ob-
served regarding CD86+ and CD274+ monocytes.
The prevalence of IDO-expressing T cells and monocytes
was higher in HP compared to NP women. At the same
time, the mean fluorescence intensity (MFI) values for IDO
were also significantly higher in both cell subsets in HP.
Plasma KYN, KYNA and TRP levels were lower, while
at the same time, the K/T ratio was higher in HP than in
NP women.
In order to explore whether reverse signalling via CD80
and CD86 is present in monocytes, correlation analyses
were performed. However, we could not detect a correlation
between the frequency of CD80+ or CD86+ monocytes and
the frequency of IDO-expressing T cells or monocytes or
the MFI of IDO in the investigated study groups.
Discussion
In this study, we aimed to characterize the prevalence of
B7 costimulatory molecules on monocytes and their corre-
sponding receptors on T lymphocytes in HP compared to
NP women, as well as the intracellular expression of IDO
and plasma levels of TRP, KYN and KYNA, important
molecules with immunoregulatory properties, in order to
describe their potential contribution to the pregnancy-
specific maternal immune tolerance. Pregnancy is an im-
munosuppressive state, with well known alterations in the
prevalence and function of T lymphocytes [1]. We as-
sumed that alterations in costimulation mechanisms via
B7 proteins might contribute to the lower level of T
lymphocyte activation compared to NP women.
However, surprisingly, the expression of CD28 was in-
creased, while that of CTLA-4 was decreased on T lym-
phocytes isolated from HP women. This finding indicates
that costimulation via CD28 is of great importance also
Figure 3 Chromatograms of the investigated molecules. a. represents the chromatogram of kynurenine (KYN) and the internal standard
3-nitro-L-tyrosine (3-NLT), made by UV detector (x: time (min), y: miliAbsorbanceUnit (mAU)). b and c. shows the chromatogram of kynurenic acid
(KYNA) and tryptophan (TRP), respectively, made by fluorescent detector (x: time (min), y: Luminescence Unit (LU)).
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the immunosuppressive environment characteristic for
gestation. At the same time, the expression of B7-1 wasdecreased on HP monocytes, while that of B7-2 was un-
altered, which might reduce the intensity of costimulation
via CD28.
Table 2 Frequency of the investigated cell surface and intracellular markers
Non-pregnant women (n = 14) Healthy pregnant women (n = 20)
CD3+ CD28+ cells/CD3+ lymphocytes 76.0 (64.7-82.9)% 88.4* (81.8-90.6)%
CD3+ CD28+ CD152+ cells/CD3+ CD28+ lymphocytes 8.90 (7.57-11.4)% 6.64* (5.07-9.89)%
CD3+ CD278+ cells/CD3+ lymphocytes 55.7 (49.5-56.7)% 89.9* (75.7-91.6)%
CD3+ CD279+ cells/CD3+ lymphocytes 46.3 (39.3-51.2)% 51.9* (47.9-67.7)%
CD4+ CD28+ cells/CD4+ lymphocytes 97.8 (96.7-98.8)% 97.3 (93.0-99.2)%
CD4+ CD28+ CD152+ cells/CD4+ CD28+ lymphocytes 6.92 (4.93-8.63)% 5.61 (3.65-9.09)%
CD4+ CD278+ cells/CD4+ lymphocytes 56.7 (52.8-59.5)% 87.7* (76.3-92.2)%
CD4+ CD279+ cells/CD4+ lymphocytes 49.4 (42.1-54.5)% 44.2 (37.5-65.2)%
CD11b + CD80+ cells/CD11b +monocytes 55.5 (17.3-69.8)% 17.6* (13.6-25.4)%
CD11b + CD86+ cells/CD11b +monocytes 23.8 (17.3-29.5)% 20.7 (14.9-31.9)%
CD11b + CD274+ cells/CD11b +monocytes 78.4 (70.3-85.9)% 80.7 (77.2-87.8)%
CD11b + CD275+ cells/CD11b +monocytes 63.8 (59.0-72.1)% 17.3* (14.1-27.0)%
CD3+ IDO + cells/CD3+ lymphocytes 5.90 (2.65-16.9)% 24.1* (13.3-56.4)%
IDO mean fluorescence intensity in CD3+ IDO + cells (arbitrary unit) 9888 (7482–11475) 62500* (19800–84475)
CD11b + IDO + cells/CD11b +monocytes 2.59 (1.99-11.7)% 22.5* (13.6-50.5)%
IDO mean fluorescence intensity in CD11b + IDO + cells (arbitrary unit) 21400 (19075–23875) 70450* (38775–114000)
*p < 0.05 versus non-pregnant women. Data are presented as median (interquartile range). IDO – indoleamine-2,3-dioxygenase, MFI – mean fluorescence intensity.
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found to be highly upregulated at the fetomaternal inter-
face and this was associated with high levels of Th1 cy-
tokines (IL-2 and IFN-gamma) and low levels of Th2
cytokines (IL-4 and IL-10) [19]. Furthermore, it was re-
ported that in vivo blockade of B7-2 costimulation
shifted the cytokine balance from a Th1 to a Th2 pre-
dominance at the fetomaternal interface, and expanded
peripheral CD4+ CD25+ regulatory T cells. Thus, reduc-
tion in the level or function of B7-2 appears to be advan-
tageous to HP in the first half of pregnancy. We could
not, however, demonstrate this reduction in third tri-
mester peripheral blood HP samples.
The expression of ICOS, a stimulator of T cell activa-
tion was strongly elevated in HP, while that of its corre-
sponding costimulatory molecule, B7-H2 was strongly
decreased on HP monocytes. Since ICOS most effect-
ively induces IL-10 instead of IL-2 production [9], its
higher level may contribute to the Th2 shift observed in
the third trimester of HP [1]. The frequency of PD-1Table 3 Plasma levels of kynurenine (KYN), kynurenic
acid (KYNA) and tryptophan (TRP)
Non-pregnant
women (n = 14)
Healthy pregnant
women (n = 20)
KYN (uM) 1.80 (1.70-2.08) 1.55* (1.31-1.83)
KYNA (nM) 29.8 (25.6-47.7) 18.8* (15.0-23.0)
TRP (uM) 54.1 (49.0-59.3) 38.6* (33.9-42.5)
K/T ratio 0.037 (0.032-0.040) 0.041* (0.038-0.045)
*p < 0.05 versus non-pregnant women. Data are presented as median
(interquartile range).expressing T lymphocytes was also elevated in HP. The
inhibitory effect of this receptor may play a role in inhi-
biting the activation of T cells during gestation. Interest-
ingly, Taglauer et al. demonstrated that the expression of
PD-1 expression on CD3 cells was low in non-pregnant
endometrium but increased in first-trimester decidua
and remained elevated in term decidua. Additionally,
higher relative proportions of term decidual CD8bright,
CD4, and Treg cells expressed PD-1 in comparison to
autologous peripheral blood, further strengthening the
role of this molecule in the development of maternal im-
mune tolerance [20].
The prevalence of IDO-producing T cells and mono-
cytes was elevated in HP compared to NP samples. The
well-known immunosuppressive activity of this enzyme
may play an important role in the development of
pregnancy-specific immune tolerance towards the de-
veloping fetus. IDO is a key enzyme in the catabolism
of tryptophan and initiates the production of kynure-
nines. These metabolites have several immunological
and non-immunological regulatory functions. By lo-
cally depleting TRP and increasing the levels of KYN
and its metabolites, IDO provides a suppression of T
cell-mediated immune response via inhibiting the pro-
liferation and inducing the apoptosis of activated T
cells, as well as promoting the development of regula-
tory T cells and tolerogenic DCs [21]. Furthermore, we
found that not only the prevalence of IDO-producing
cells, but also the intracellular amount of IDO is ele-
vated in HP (represented by the higher MFI values
compared to NP women).
Figure 4 Frequency of the investigated cell surface markers on CD3+ lymphocytes and CD11b +monocytes. Horizontal line – median,
box – interquartile range, whisker – range. NP – non-pregnant women, HP – healthy pregnant women. *p < 0.05 vs NP.
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in HP, resulting in an elevated K/T ratio compared to NP.
As noted above, the depletion of TRP may directly con-
tribute to the immunosuppressive environment in HP.
The increase in IDO activity in HP (represented by the el-
evated K/T ratio) corresponds well with our finding of
higher IDO-expressing T cell and monocyte numbers
in HP. Interestingly, although the prevalence of IDO-
producing T cells was decreased in our earlier study in PE
compared to HP [22], KYN, KYNA and TRP levels, as well
as the K/T ratio were comparable in HP and PE (1.55
(1.31-1.83) vs. 1.67 (1.33-1.93) uM, 18.8 (15.0-23.0) vs.
22.3 (16.7-28.5) nM, 38.6 (33.9-42.5) vs. 37.1 (30.0-41.3)
uM, 0.041 (0.038-0.045) vs. 0.044 (0.036-0.049), respect-
ively). Hence, the alterations observed in the frequency of
IDO-producing cells are not reflected by the enzymatic ac-
tivity of IDO in PE, in contrast to HP.
Another reason for decreased KYN, KYNA and TRP
levels in HP compared to NP may be the fact that these
molecules cross the placenta via yet partly unidentified
mechanisms and transporters, and contribute to the devel-
opment of the decreased immune responsiveness of the
fetus. Our unpublished recent data, indicating elevated
KYN, KYNA and TRP levels in cord blood of healthy term
neonates compared to adult peripheral blood may support
this assumption. However, further experimental data are
needed to confirm or refute this hypothesis.
The engagement of B7-1 and B7-2 by CTLA-4 induces
back signalling into the monocyte and promotes the pro-
duction of IFN-gamma, which acts in an autocrine or
paracrine manner to upregulate IDO expression, thereby
initiating the degradation of TRP and resulting in an im-
munosuppressive effect as described above. Thus, the
interaction between CTLA-4 and B7 proteins plays twodifferent roles: first, at the level of T cells where CTLA-4
as a negative receptor regulates TCR signal transduction;
second, at the level of APCs where CTLA-4 as a ligand
signals to the APC to induce IDO expression [23]. We
hypothesized that reverse signalling may play a role in
the higher IDO activity and expression observed in HP.
However, correlation analyses with B7-1 and B7-2 ex-
pression did not support this notion.
Conclusions
In conclusion, costimulation via CD28 may not contribute
to the immunosuppressive environment, at least in the last
stage of pregnancy. Based on our findings, the develop-
ment of the pregnancy-specific immune tolerance in the
mechanism of B7 costimulation may be more related to
the altered expression of B7 proteins on APCs rather than
that of their receptors on T cells. The elevated intracellular
IDO expression in monocytes and T cells, as well as higher
plasma enzymatic IDO activity are likely to contribute to
the systemic immunosuppressive environment in the third
trimester characteristic for healthy gestation.
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